SOURCE: Daxor Corp.

Daxor Corp.

February 17, 2016 09:00 ET

Daxor Corporation Announces Return of Dr. Joseph Feldschuh After Pancreatic Cancer Surgery

NEW YORK, NY--(Marketwired - Feb 17, 2016) - Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces Dr. Joseph Feldschuh, CEO of Daxor, Returns to Work After Medical Leave

On December 14, 2015 Dr. Feldschuh undertook a medical leave of absence. At that time the Board of Directors of Daxor appointed Michael Feldschuh, previously the Executive Vice President of the corporation, as the interim President and CEO.

Dr. Feldschuh stated: "After experiencing some mild weight loss and other minor symptoms, I contacted my personal physician, Dr. David Seinfeld, on December 2, 2015. Though my symptoms were somewhat nonspecific and of short duration, after 24 hours Dr. Seinfeld arranged for a high resolution abdominal CT scan, which revealed a pancreatic cancer tumor that, fortunately, was still at an operable stage. Eighty-five percent of pancreatic cancers, when discovered, are beyond an operable stage."

Having met with three surgeons at three leading facilities possessing world-class expertise and experience in the necessary surgical procedure, Dr. Feldschuh selected Dr. Myron E. Schwartz, the Henry Kaufmann Professor of Surgery Director of Liver Surgery Recanati/Miller Transplantation Institute of Mount Sinai Hospital, to be his surgeon. The operation was performed on December 17, within two weeks of the diagnosis. The pathologist's report confirmed that the margins of the tissue removed were free of cancer. 

Dr. Feldschuh returned to work in the first week of February, resuming his core responsibilities as Chief Scientific Officer and Director of Lab Services. Michael Feldschuh retains his present position as interim President and CEO.

Dr. Feldschuh stated: "I am grateful for the diagnostic skills of my physician, Dr. David Seinfeld, and for the surgical skills of Dr. Myron Schwartz. They have given me hope that I may be among the fortunate survivors of this disease. I also appreciate the excellent care that I received at the Mount Sinai Medical Center."

Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single use diagnostic kit. The instrument is the only FDA approved semi-automated instrument to provide this test. Preliminary results can be available in 30 minutes and complete results in under an hour.

To learn more about Daxor, please visit www.Daxor.com.

Contact Information